Novo Nordisk A/S (NVO) Stock

About Novo Nordisk A/S

Novo Nordisk A/S is led by CEO Maziar Mike Doustdar, employs 77,406 people, headquartered in Bagsvaerd, DK, publicly traded since 1981.

Novo Nordisk A/S (NVO) stock trades at $38.83 with a market capitalization of $171.36B. The stock is valued at a price-to-earnings (P/E) ratio of 9.65, price-to-book of 5.06, price-to-sales of 3.41. Over the past 52 weeks the stock has ranged between $35.12 and $64.16, and currently trades 39.5% below its 52-week high. It pays a dividend yielding 2.99%.

On profitability, Novo Nordisk A/S generates a return on equity (ROE) of 59.09%, above the typical market range of roughly 12-15%, return on capital employed of 39.93%, an operating margin of 41.30%, a net profit margin of 35.35%.

In its most recent fiscal year, Novo Nordisk A/S reported annual revenue of $309.1B, net profit of $102.4B. Over the last 5 fiscal years, revenue grew at an average annual rate of 19.5%, and net profit grew at an average annual rate of 19.4%.

The balance sheet shows a debt-to-equity ratio of 0.63, a current ratio of 0.80, total assets of $542.9B, $26.5B in cash and equivalents.

NVO has a beta of 0.35 (historically less volatile than the overall market).